Home › Funds › FRONTIER CAPITAL MANAGEMENT CO LLC › BBIO

FRONTIER CAPITAL MANAGEMENT CO LLC position in BBIO

BRIDGEBIO PHARMA INC · Health Care

FRONTIER CAPITAL MANAGEMENT CO LLC reported holding 1,373,057 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$102.3M, representing 0.95% of its reported portfolio and ranking #15 among its reported holdings. FRONTIER CAPITAL MANAGEMENT CO LLC has disclosed BBIO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.37M sh
Reported value held$102.27M
Portfolio Weight0.95%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FRONTIER CAPITAL MANAGEMENT CO LLC's BBIO position evolved

FRONTIER CAPITAL MANAGEMENT CO LLC first disclosed a stake in BBIO in Q1 2024 at 449,536 shares (US$13.9M). The position peaked in Q2 2026 at 1,373,057 shares, worth US$102.3M. Across 10 filings, FRONTIER CAPITAL MANAGEMENT CO LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,373,057 shares valued at US$102.3M — an increase of 415,068 shares quarter over quarter.. Notable position changes include a 67% trim in Q2 2024 (shares were roughly flat over the following quarter), a 239% increase in Q3 2024 (shares rose 8% over the following quarter), a 114% increase in Q4 2024 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 449.54K $13.90M New
Q2 2024 148.37K $3.76M Reduce
Q3 2024 503.16K $12.81M Add
Q4 2024 1.08M $29.52M Add
Q1 2025 769.30K $26.59M Reduce
Q2 2025 535.76K $23.13M Reduce
Q3 2025 659.63K $34.26M Add
Q4 2025 826.13K $63.19M Add
Q1 2026 957.99K $71.14M Add
Q2 2026 1.37M $102.27M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has FRONTIER CAPITAL MANAGEMENT CO LLC held BBIO?

FRONTIER CAPITAL MANAGEMENT CO LLC has disclosed BBIO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is FRONTIER CAPITAL MANAGEMENT CO LLC's current position in BBIO?

As of Q2 2026, FRONTIER CAPITAL MANAGEMENT CO LLC holds 1.37M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $102.27M, representing 0.95% of its reported portfolio and ranking #15.

Has FRONTIER CAPITAL MANAGEMENT CO LLC been buying or selling BBIO?

In the latest 13F filing (Q2 2026), FRONTIER CAPITAL MANAGEMENT CO LLC increased its position in BBIO. The position peaked in Q2 2026 at 1.37M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.